p53 is a healthcare investment company based on a belief in long-term value creation.

P53’s portfolio company Arxx Therapeutics is joining forces with Oxitope Pharma to form Calluna Pharma. We are thrilled to continue this exciting journey and take part in the subsequent Series A round lead by Forbion. P53 has had the privilege to work with the Arxx team over time as the first investors - together with Sarsia - back in 2019. The merger, and subsequent Series A round is a considerable validation of the science and hard work that has been done by the team over the years. 
 
This deal epitomizes what we seek to accomplish in p53: to contribute to the development and commercialization of ground-breaking ideas that transform people’s lives, increase accessibility to cutting-edge treatments and innovative healthcare solutions and create exceptional value for patients.
 
We look forward to work with partners - established and new - to contribute to the success of Calluna Pharma.

Jonas Hallén Jörg Klingelhöfer Berte Poulsson Sylvia Vetrhus Kjell Skappel Oystein Soug Sarsia Investinor Susanne Stuffers, MD PhD Erlend Skagseth Sveinung Hole Farzad Abdi-Dezfuli Birgitte Gangmark Villmo Kari Grønås (prev. Dyvik) Dr. Christian Schweiger MD PhD Yuri Khodjamirian, CFA Rizwan I. Hussain Advokatfirmaet Schjødt

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 4, 2024 1:42 AM	6aaced99
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 4, 2024 2:28 AM	daa8353d
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	4e52e263
crunchbase profile	general
li profile	general	Sep 4, 2024 1:42 AM	a6d2c27c
translate crunchbase fundingrounds	general
peers	general	Sep 4, 2024 1:42 AM	ffa39a01
news basic	general	Sep 4, 2024 1:42 AM	5f7b7b6e
bundesanzeiger	filings
financials download nd	financials
private financials	financials

P53

NO:P53

p53